Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013; 14 :1095–1103.Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, Tu YK. Adjuvant treatments for resected pancreatic adenocar- cinoma: a systematic review and ...
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis Lancet Oncol, 14 (2013), pp. 1095-1103 View PDFView articleView in ScopusGoogle Scholar 12 JP Neoptolemos, T Cox Bayesian analysis unravels pancreas cancer adjuvant therapy Lancet Oncol, 14 (20...
pancreatic cancerpostoperativePurpose: This study aimed to investigate the cost-effectiveness of adjuvant treatments in resected pancreatic cancer. Methods: A Markov model was developed to mimic the disease process of postoperative pancreatic cancer, encompassing three health states (relapse-free survival, ...
Bergenfeldt M,Albertsson M.Current state of adjuvant therapy in resected pancreatic adenocarcinoma.Acta Oncologica. 2006Bergenfeldt M, Albertsson M. Current state of adjuvant therapy in re- sected pancreatic adenocarcinoma. Acta Oncol 2006; 45: 124 ± 135...
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57. Article CAS Google Scholar Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and ...
EP: 12.Emerging Treatments for Advanced Melanoma Evan J. Lipson, MD: CheckMate 238 is an important study. It is a multicenter, double-blind, randomized phase 3 trial. It’s in the adjuvant setting for patients with resected stage IIIB, IIIC, or IV melanoma by the AJCC [American Joint ...
et al. Neoadjuvant and adjuvant systemic therapies in loco-regional treatments for hepatocellular carcinoma: are we at the dawn of a new era? Cancers (Basel) 15, 2950 (2023). Article CAS PubMed Google Scholar Cheng, A.-L. et al. Efficacy and safety of sorafenib in patients in the ...
Currently, the generally accepted adjuvant treatment paradigm for resected pancreatic cancer in the USA is a period of full-dose chemotherapy (usually with gemcitabine), followed by chemoradiation. This approach serves two purposes. First, since distant metastasis is the primary cause of cancer-related...
The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other anti–PD-1/PD-...
Collectively, these findings suggest that improving strategies for systemic control should take priority in resected pancreatic cancer. Adjuvant strategies in pancreas cancer: assessing the value of treatment options Given the lack of evidence of benefit of adjuvant CRT in comparison to CT in resected ...